Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06146322 · ClinicalTrials.gov registry record · NA

Barley Beta-glucan, Glycemic Control, and Appetite

A NA study of Diabetes and Diet, Healthy, sponsored by Washington State University.

Completed
Registry status
NA
Development phase
16
Enrollment target
1
Study location

NCT06146322 is a NA study of Diabetes and Diet, Healthy that has completed, run by Washington State University. The registered enrollment target is 16 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06146322, a NA study of Diabetes and Diet, Healthy, has completed, sponsored by Washington State University.

COMPLETED
Registry status
NA
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

Novel barley varieties high in the soluble fiber β-glucan have the capacity to improve population health through improving glycemic control. Sweetened and unsweetened wholegrain barley foods were tested in a randomized, controlled, crossover human clinical trial to assess impact on postprandial appetite and food intake.

Interventions

  • OTHER WR
  • OTHER LB
  • OTHER MB
  • OTHER HB
  • OTHER WR+50g HFCS

Study Locations (1)

Washington

  • Washington State University - Spokane

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2019-10-01
Est. Completion 2020-10-31
Phase NA

Sponsor

Washington State University

64 total trials

What the Registry Record Tells You About NCT06146322

The ClinicalTrials.gov registry entry for NCT06146322 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The listed sponsor is Washington State University, which has 64 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Diabetes appearing as the primary indexed condition, and to 5 interventions - of which WR is the first listed.

NCT06146322 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT06146322 about?

NCT06146322 is a clinical study titled "Barley Beta-glucan, Glycemic Control, and Appetite". Novel barley varieties high in the soluble fiber β-glucan have the capacity to improve population health through improving glycemic control. Sweetened and unsweetened wholegrain barley foods were tested in a randomized, controlled, crossover human clinical trial to assess impact on postprandial appe...

What is the current status of trial NCT06146322?

This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2019-10-01. Estimated completion is 2020-10-31.

What conditions does trial NCT06146322 study?

This clinical trial studies the following conditions: Diabetes, Diet, Healthy, Appetitive Behavior, Blood Sugar; High, Appetite and General Nutritional Disorders.

What interventions are being tested in trial NCT06146322?

The interventions under investigation include: WR (OTHER), LB (OTHER), MB (OTHER), HB (OTHER), WR+50g HFCS (OTHER).

Who is sponsoring clinical trial NCT06146322?

This trial is sponsored by Washington State University, which has 64 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06146322 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.